CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021 May 3, 2021
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity Apr 21, 2021
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity Mar 29, 2021
CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021 Mar 16, 2021
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases Mar 16, 2021
